Clinical Trials Directory

Trials / Completed

CompletedNCT01491971

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Open-label, Multi-centre, Parallel Group Dose-Escalation Trial Assessing the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
76 (actual)
Sponsor
Ferring Pharmaceuticals · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients with Prostate Cancer.

Conditions

Interventions

TypeNameDescription
DRUGDegarelix

Timeline

Start date
2012-01-01
Primary completion
2012-11-01
Completion
2012-11-01
First posted
2011-12-14
Last updated
2013-12-12

Locations

15 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT01491971. Inclusion in this directory is not an endorsement.

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer (NCT01491971) · Clinical Trials Directory